AnGes, Inc.
4563・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 5 directors (including 3 outside directors, outside ratio 60%), and the Board of Corporate Auditors consists of 3 corporate auditors (all outside). Director term of office is 1 year. The establishment of a nomination committee and compensation committee is not stated in the securities report. In February 2026, the Board of Directors resolved to introduce a peacetime-type takeover defense measure (free allotment of stock acquisition rights) against large-scale purchases involving a voting rights ratio of 20% or more.
Risk Management
The "Risk Management and Compliance Committee" (meeting once per quarter), chaired by the Representative Director, centrally manages company-wide risks. Key management risks are classified into "strategic risk" and "operational risk," with sustainability risk positioned as one type of strategic risk. Important risks are reported to and overseen by the Board of Directors. The company discloses that material uncertainty exists regarding its ability to continue as a going concern.
Shareholder Returns
The company is in the drug discovery investment phase and continues to forgo dividends at this time. The projected annual dividend for FY2026 (ending December 2026) is ¥0.00. No share buybacks have been conducted. The policy is to consider dividends in the future once developed pharmaceuticals reach market launch, profits are recorded, and distributable amounts arise.
Dividend Policy
The actual annual dividend for FY2025 (ending December 2025) was ¥0.00 (¥0.00 for both interim and year-end). The projected annual dividend for FY2026 (ending December 2026) is also ¥0.00 (¥0.00 at second-quarter-end and ¥0.00 at year-end). Due to continued operating losses and negative operating cash flow, dividends from surplus have been withheld. The policy is to consider dividends in the future, once pharmaceuticals under development reach market launch and sales generate profits and a distributable amount arises, taking into account business performance and financial condition at that time. There has been no revision from the most recently announced dividend forecast.
ESG
With the SDG goal of "Good Health and Well-being" as its foundation, the company aims to contribute to society through the development of innovative pharmaceuticals addressing unmet medical needs. It positions human capital as a source of value, and the ratio of female managers reached 47.1% (16 out of 34) in 2025, reflecting active promotion of diversity. No quantitative human capital targets have been set. No specific disclosures regarding climate change are included in the Annual Securities Report.
Last updated: March 25, 2026